A phase I/II dose escalation and efficacy trial of GVAX prostate cancer vaccine [Cancer vaccine-GVAX] in patients with metastatic hormone-refractory prostate cancer

Trial Profile

A phase I/II dose escalation and efficacy trial of GVAX prostate cancer vaccine [Cancer vaccine-GVAX] in patients with metastatic hormone-refractory prostate cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2008

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cell Genesys
  • Most Recent Events

    • 23 Jul 2008 Cell Genesys announces publication of final results from this trial; results are consistent with thiose seen in the first phase II trial and sup[port the phase III trial program.
    • 18 Dec 2007 Status changed from in progress to completed.
    • 04 Apr 2007 Final survival data presented.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top